Mid-teen worries; 'Buy' ratings on Glenmark Pharma shares: Motilal Oswal

May 19 2014, 07:10 IST
Comments 0
SummaryA slow year ahead on low growth expectation in US market

Tarka litigation penalty impacts reported PAT: Glenmark Pharmas (GNP) Q4 operational performance was in line with our expectations. Reported sales grew 26% y-o-y to R16.8 bn (our estimate: R16bn) and reported Ebitda grew 34% y-o-y to R3.6 bn (our est. R3.5 bn). However, reported PAT declined 74% y-o-y to R453m (our est. R2 bn) due to exceptional expenditure towards Tarka litigation penalty.

Adjusted for low competition launches and out-licensing income, sales grew 27% y-o-y, Ebitda grew 32% and profit after tax grew 17%. Core Ebitda margin was at 19.7%.

Growth slower in US and India: Growth was stronger than expected in APIsactive pharmaceutical ingredients--(up 63% vs our est. of 37%), Europe (up 30% vs our est. of 8%) and semi-regulated markets (up 55% vs our est. of 14%). Growth for the US and India slowed down during the quarter due to erosion in base business and base effect, respectively.

Guidance for FY15: GNP has guided 16-18% revenue growth for FY15, with Ebitda at R15 bn-15.2 bn. Growth would be strong in emerging markets and Europe (on a low base), and recover to above 18% in India. US business is likely to grow 12-15%, given the lack of clarity on new approvals. R&D expenses would be 9.5-10% and tax rate is likely to be 22%. Capex guidance stands at R4.5 bn-5 bn. The management expects a reduction in net debt.

Raising EPS estimates; maintain Buy: FY15 is shaping up to be a slow year for GNP mainly due to mid-teens growth expectation in the US. Growth drivers in India and key semi-regulated markets remain strong. Higher R&D spends are likely to result in muted margin expansion. We do not expect any major reduction in debt during FY15. However, we expect FY16 to be a stronger year for the US. We maintain Buy with a revised target price of R665.

Takeaways from conference call

Guidance for FY15e: The management has guided for 16-18% revenue growth, with Ebitda expected in the range of R15-15.25 bn. R&D expenses are guided to be in the range of 9.5-10% while tax rate is expected to be 22%.

US business is expected to grow in the range of 12-15% on a constant currency basis. The management expects 3-4/10-12 product launches in Q2/FY15 which will lead to a recovery in growth. Key future launches include gFinacea (FY16) and gZetia (FY17e). GNP is also developing products in niche areas like complex injectables,

Single Page Format
Ads by Google

More from Cover Story

Reader´s Comments
| Post a Comment
Please Wait while comments are loading...